December 22, 2009 — Intravitreal use of the corticosteroid triamcinolone may slow the progression of diabetic retinopathy, but adverse effects including cataract formation and glaucoma may ...

A report in the December issue of the Archives of Ophthalmology shows that injecting the corticosteroid triamcinolone into the eye may slow the progression of diabetic retinopathy, a complication of ...

Injecting the corticosteroid triamcinolone into the eye may slow the progression of diabetic retinopathy, a complication of diabetes that can cause vision loss and blindness, according to a new study.

To evaluate the effect of intravitreal triamcinolone in eyes with diabetic macular oedema that had no previous laser treatment. In all, 12 eyes of 12 patients with diabetic retinopathy, aged 47 ...

Efficient and accurate diagnosis of diabetic retinopathy, risk assessment, and treatment are critical, given the disease burden. Globally, from 1990 to 2010, visual impairment due to diabetic ...

Geriatrics and Aging. 2008;11(6):333-341. Proliferative diabetic retinopathy is clinically characterized by the growth of new blood vessels that arise from the optic disc and/or retina and ...

Early treatment . Some physicians view laser photocoagulation – as outlined in the Early Treatment Diabetic Retinopathy Study – as the standard of first-line care in non-traction diabetic ...

Evidence-based recommendations on fluocinolone acetonide intravitreal implant (Iluvien) for visual impairment caused by chronic diabetic macular oedema that has not responded well enough to available ...

It noted that in the optimised standard of care group, people with diabetic macular oedema for more than 3 years showed lower levels of response (13.4% of patients) than people with diabetic macular ...